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Abstract
The aim of this study was to assess the prevalence of exposure to topical
nonsteroidal anti-inflammatory drugs (NSAIDs), particularly ketoprofen, in a
convenience sample of the population, to obtain estimates of the incidence
of severe photosensitivity leading to hospitalization, and to assess causative
factors in three catchment areas: the Paris metropolitan area, the Lombardy
region (Italy) and the Prague area. All cases of severe photosensitivity not
explained by underlying conditions and admitted to hospitals in the selected
areas were included in the study. Controls were patients consecutively admit-
ted to hospitals, in the same areas, for an acute condition or for an elective
procedure not suspected of being related to medication use. From October
2012 to September 2013, 920 controls were recruited (median age 44 years,
50.8% females); 8 severe photosensitivity cases were reported in the popula-
tion aged 18–74 years of the 3 geographical areas during the 1-year surveil-
lance period, corresponding to an incidence rate of 4.81 cases per 10 million
person-years (95% confidence interval – CI, 2.07–9.48). Six controls reported
1-month exposure to topical ketoprofen, with an estimated prevalence of
0.65% (95% CI, 0.24–1.42). The population attributable risk for severe pho-
tosensitivity reactions linked to ketoprofen was 11.92% (95% CI, 0.12–
52.99). This study was conducted in selected European areas and showed
that the incidence of severe photosensitivity reactions leading to hospitaliza-
tion as well as the exposure rate to topical ketoprofen were low. Among
topical NSAIDs, topical ketoprofen was the leading cause of photosensitivity
reactions but accounted for a limited number of hospitalized cases. Probably
most of the relevant reactions were managed in the outpatient setting and a
community based case–control study is advisable.
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
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Abbreviations
BMI, body mass index; ICC, intraclass correlation coefficient; NSAID, nonsteroidal
anti-inflammatory drug; OR, odds ratio; PACD, photoallergic contact dermatitis;
PAR, population attributable risk.
Introduction
Ketoprofen is a nonsteroidal anti-inflammatory drug
(NSAID) with anti-inflammatory, analgesic, and antipyre-
tic properties. It is available in several forms including
oral, parenteral, and topical preparations. The topical
form of ketoprofen usually consists of a 2.5% to 5% gel,
but there are other formulations (e.g., cream, liquid
spray) and other strengths available. Topical ketoprofen is
used to treat pain and inflammation in conditions such
as minor trauma (sprains, bruising), tendonitis, small-
joint osteoarthritis, acute low-back pain, and phlebitis.
Topical ketoprofen is used in more than 70 countries
worldwide. Since its first market authorization in Europe
in 1972, cases of photoallergic contact dermatitis related
to ketoprofen use have been described and characterized
(Bagheri et al. 2000; Matthieu et al. 2004; Cantisani et al.
2010; Noize et al. 2010). To date, however, there is lim-
ited information on the incidence of severe photosensitiv-
ity reactions leading to hospitalization among topical
ketoprofen users as compared with users of other topical
NSAIDs. From spontaneous surveillance data, in France,
originated in different areas and different time periods, it
was estimated that the frequency of reporting of any cuta-
neous adverse events attributed to topical ketoprofen ran-
ged from 0.8 to 2.8 per 100,000 inhabitants per year and
that around 6–18% of these cutaneous side-effects were
cases of photoallergy leading to hospitalization (Baudot
et al. 1998; Veyrac et al. 2002; Noize et al. 2010). In an
analysis of spontaneous reports in Italy, the observed
reporting rate of photosensitivity reactions from any
causes was 5.5 per 100,000 inhabitants per year and the
rate of serious photosensitivity reactions was 0.09 per
100,000 inhabitants per year (Naldi et al. 1999). In
another study conducted in Spain using clinical records
of subjects with contact allergy and/or photoallergy due
to topical NSAIDs, the rate of photoallergic reactions was
1.2 per 100,000 per year (Diaz et al. 2006). In order to
better define the risk profile of topical ketoprofen use, as
requested by the European Medicines Agency (EMA) in
2010, an epidemiologic case–control study was proposed
focusing on severe photosensitivity reactions leading to
hospitalization and assessing risks linked with the use of
topical ketoprofen and other topical NSAIDs for these
reactions. This paper reports the results of the pilot feasi-
bility phase of this study. The aims of the pilot phase
were first to assess the prevalence of exposure to topical
NSAIDs and specifically topical ketoprofen in a conve-
nience sample of the population; second to develop diag-
nostic criteria for severe photosensitivity with special
focus on photoallergic contact dermatitis (PACD), already
reported elsewhere (Cazzaniga et al. 2015), and third to
obtain estimates of the incidence of severe photosensitiv-
ity leading to hospitalization in selected sampling areas.
Materials and Methods
The study was implemented as an incidence study linking
incidence data with population drug exposure estimates
derived from interviewing hospital controls deemed to be
representative of the general population. Three geographi-
cal areas were surveyed: the Paris metropolitan area in
France, the Lombardy region in Italy, and the Prague area
in the Czech Republic. All procedures performed in this
study were in accordance with the ethical standards of the
institutional and/or national research committee and with
the 1964 Helsinki declaration and its later amendments
or comparable ethical standards, and was approved by the
ethical committees in each of the selected catchment
areas: Ethics Committee of the province of Bergamo (res-
olution n. 997/2012); Institutional Review Board for the
Protection of Human Subjects of Henri Mondor Hospital,
Paris (resolution n. 2012/38NICB); Ethics Committee of
Bulovka Hospital, Prague (resolution n. 7.8.2012/488/EK-
Z). The general scheme of the study is shown in Figure 1.
Collection of cases
This component of the study involved the identification,
during the 1-year surveillance period, of all cases of severe
photosensitivity from any cause admitted to hospitals in
the surveyed areas (including Emergency Department
admissions and 1-day admissions). The diagnostic criteria
employed were in agreement with those developed during
the first phase of our study (Cazzaniga et al. 2015). Seven
criteria were identified by experts as relevant for the diag-
nosis of PACD. The criteria were related to the type of
skin lesions, accompanying symptoms, skin area involved,
general medical history, modality of exposure to the cul-
prit substance, history of exposure to the sun or other
light sources and photopatch test results.
All patients, aged between 18 and 74 years, admitted
for a skin reaction associated with vesicles and/or bullae,
involving one or several body areas, with a positive
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history of sun exposure in the last month or week before
hospitalization, and with a clinical diagnosis of photosen-
sitivity reaction were included in the study. Patients with
reactions attributable to the underlying diseases (e.g., sys-
temic lupus erythematous) and immunologically mediated
photodermatoses (e.g., polymorphic light eruption) were
excluded from the analysis. Patient’s information was
retrieved from hospital records and direct patient inter-
view. Informed consent had been obtained from the
patient in the latter case. Data on general demographics,
suspected culprit substance, administration route, formu-
lation, severity, and clinical outcome were collected. Drug
exposure was defined as the use of drugs or medications
within 1 month prior to the index date, i.e., the date of
hospitalization. Drug exposure was assessed using a struc-
tured day by day questionnaire for the week preceding
the index date and week by week for the preceding
3 weeks.
In addition to hospital surveillance, in the Lombardy
region, cases were collected through two major study
databases: MEREAFaPS and FARMAMONITO (Galfras-
coli et al. 2012). The REACT network was also alerted for
the reporting of photosensitivity cases and cross-checked
with other registries for consistency and completeness
(Gamba et al. 2014). For the Prague area, Directors of
Dermatology Departments in every hospital of the area
had been asked to report retrospective as well as
prospective cases to the local Coordinating Centre. For
the Paris area, all cases were retrieved through the French
Pharmacovigilance Database and direct surveillance of
hospitals in the area (Durrieu et al. 2013).
Control data
This part of the study involved the identification and
interview of a sample of patients of both genders, aged
between 18 and 74 years, consecutively admitted to hospi-
tals in the geographic areas participating in the pilot
phase and satisfying entry criteria for controls usually
adopted in pharmacoepidemiologic case–control studies
(Slone et al. 1977), namely, patients admitted for an acute
condition or for an elective procedure not suspected of
being related to medication use. Conditions included:
traumatic injuries, acute infections, abdominal emergen-
cies, elective surgery such as hernia repair, ocular, nose,
and throat procedures. Patients with chronic disorders
were eligible if hospitalized for an unrelated acute disease
but not if admitted for an acute exacerbation of their
chronic disease. Patients admitted for any skin problem
suspected to be related to photosensitivity were excluded.
The eligible controls were contacted and once informed
consent had been obtained were interviewed according to
a standardized questionnaire exploring medication use as
well as other items such as demographics, recent and past
Figure 1. Flow chart of the study, representing data collection in selected catchment areas and outcomes of interest.
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
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medical history (including reactions to topical NSAIDs),
history of sun exposure during the last week and month
preceding hospitalization, phenotypic features, and envi-
ronmental exposure. Drug exposure for controls was
defined in the same way as for cases.
A proportionate stratified sampling design without
replacement was used in order to obtain a representative
sample of the population within each geographical area
(Kalton 1983). In the sampling plan, the distribution of
the population by age, gender, and geographic location
was accounted for. In each participating hospital, staff
nurses and physicians were trained regarding proper data
collection and coding system used for the interview before
the beginning of the study. Interviews were performed
within 10 days from hospital admission so as to ensure a
proper recall of events prior to hospitalization.
Statistical analysis
Numerical data are presented as medians with ranges,
while categorical data as numbers with percentages. One-
month drug exposure prevalence rates were calculated
along with their exact (Clopper-Pearson) 95% confidence
intervals (CI) (Newcombe 1998). To estimate the repre-
sentativeness of collected controls in relation to the popu-
lation of catchment areas, a comparison of general
characteristics of individuals undergoing the interview
and their exposure rates to topical ketoprofen with the
expected distribution, based on census and IMS sales data
obtained from individual areas in the period 2012–2013,
were made. The assessment was done by comparing 95%
CI for the difference between proportions or medians
against fixed tolerances. These were: 5% for gender,
5 years for age distributions and 1% for topical keto-
profen exposure. Reproducibility of selected items of the
questionnaire was assessed by calculating Cohen’s kappa
for nominal variables (Cohen 1960), and by one-way sin-
gle measure intraclass correlation coefficient (ICC) for
ordinal or continuous variables (McGraw and Wong
1996), together with their 95% CI. Values of Cohen’s
kappa and ICC greater than 0.60 indicate an acceptable
reliability of questionnaire variables.
In the design of the study we estimated, based on IMS
sales data, that the 1-month prevalence of exposure to
NSAIDs was not lower than 0.5%. Hence a sample of
about 900 controls (300 per centre) would had ensured a
95% CI total width equal or lower than 1% for a preva-
lence of no more than 0.5%. During the study, however,
the number of controls had been adjusted per area based
on relative ability to enrol patients.
Incidence rates were calculated, together with their
exact 95% CI, by pooling the data in each region based
on their relative sample size.
In order to summarize the study results in a single
measure that takes into account the impact of individ-
ual drug exposure on the disease incidence, the popula-
tion attributable risk (PAR) was used. PAR estimates
the number of cases in the total population that are
attributed to an exposure factor, taking into account
both the risk ratio and the prevalence of exposure in
the general underlying population. It can assume both
positive and negative values, for risk or protective fac-
tors respectively, ranging from 100% to 100%. In our
study, the indirect method proposed by Cole and Mac-
Mahon (1971) was used. 95% CI for PAR was calcu-
lated by using the substitution method (Daly 1998),
where the population-exposure was treated as a fixed
factor while the 95% CI for the odds ratio (OR) was
calculated by using exact mid-P estimate (Berry and
Armitage 1995). When required, a continuity correction
was applied in the computation of the OR and expo-
sure prevalence (Cox 1970). Statistical analysis was per-
formed using SPSS software, version 17.0 (SPSS,
Chicago, IL).
Results
From October 2012 to September 2013, a total of 920
controls were recruited, 370 (40.2%) in the Lombardy
region (Italy), 300 (32.6%) in the Paris metropolitan
area (France), and 250 (27.2%) in the Prague area
(Czech Republic). This is consistent with the sample
size estimation given in the design of the study. Gen-
eral data and main demographics of controls, by geo-
graphical region and overall, are reported in Table 1.
The median age of subjects interviewed was 44 years
ranging from 18 to 74 and 50.8% of them were
women. The age and gender distribution was consistent
with that of the underlying population in each area,
with an overall difference of 0.07% (95% CI, 3.30–
3.16) with the general population proportion of women
and of 0 years (95% CI, 2–2) with the population
age distribution. The median BMI of controls was
24.9 kg/m2; most of people were workers (59.1%) or
retired (19.0%) and with a high-school degree (55.3%).
Here, 29.3% were smokers and 52.7% occasional
drinkers, with slight variations among countries.
Table 2 reports lifetime history of skin conditions for
controls. Most common skin diseases during the life-
time were: atopic dermatitis (2.9%), psoriasis (2.7%),
and urticaria (2.5%). Three subjects (0.3%) reported an
allergic reaction to topical ketoprofen during the life-
time, one of which was hospitalized (0.1%); six controls
(0.7%) reported an allergic reaction to other topical
NSAIDs during the lifetime and none of these was
hospitalized.
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Drugs exposure prevalence
Table 3 shows the estimated 1-month prevalence of expo-
sure to selected medications in the control group , by the
geographical region involved and overall. The 1-month
prevalence of exposure to topical ketoprofen was 0.65%
(95% CI, 0.24–1.42), ranging from 0% (95% CI, 0–0.99)
for Lombardy and Prague (95% CI, 0–1.46) to 2.02%
(95% CI, 0.74–4.34) for Paris; for other topical NSAIDs it
was 3.07% (95% CI, 2.05–4.41), ranging from 0% (95%
CI, 0–1.47) for Prague to 8.22% (95% CI, 5.34–11.98) for
Paris. The prevalence of exposure to systemic NSAIDs
during the last month was 17.44% (95% CI, 15.02–20.07)
and for other systemic drugs was 42.56% (95% CI, 39.33–
45.84). The 1-month exposure rates to topical ketoprofen
was quite consistent with the estimates derived from IMS
Table 1. General data and main demographics of controls, by geographical region and overall.
Geographical region
Lombardy (N = 370) Paris area (N = 300)
Prague area
(N = 250) Total (N = 920)
n1 % n1 % n1 % n1 %
Gender
Female 187 50.5 157 52.3 123 49.2 467 50.8
Male 183 49.5 143 47.7 127 50.8 453 49.2
Age (years) Median (range) 45.0 18–74 44.0 18–74 42.5 18–74 44.0 18–74
18–34 104 28.1 94 31.3 74 29.6 272 29.6
35–54 136 36.8 117 39.0 95 38.0 348 37.8
55–74 130 35.1 89 29.7 81 32.4 300 32.6
BMI (kg/m2)
Median (range) 24.4 14.4–50.9 24.8 14.0–49.8 26.2 16.7–76.4 24.9 14.0–76.4
<25.0 210 57.4 149 52.3 96 38.9 455 50.7
25.0–29.9 119 32.5 94 33.0 93 37.7 306 34.1
30.0 37 10.1 42 14.7 58 23.5 137 15.3
Marital status
Married/common-law husband/wife 230 62.2 164 54.7 143 57.2 537 58.4
Unmarried 109 29.5 94 31.3 72 28.8 275 29.9
Divorced/widowed 29 7.8 41 13.7 35 14.0 105 11.4
Other 2 0.5 1 0.3 0 0.0 3 0.3
Occupational status
Working 204 55.1 174 58.0 166 66.4 544 59.1
Student 12 3.2 12 4.0 15 6.0 39 4.2
Unemployed/searching for a job 27 7.3 37 12.3 8 3.2 72 7.8
Retired 77 20.8 53 17.7 45 18.0 175 19.0
Disability pension 9 2.4 6 2.0 4 1.6 19 2.1
Housewife/househusband 38 10.3 17 5.7 7 2.8 62 6.7
Other 3 0.8 1 0.3 5 2.0 9 1.0
Highest level of education
Compulsory education not completed 49 13.3 8 2.7 1 0.4 58 6.3
Compulsory education 63 17.1 94 31.3 8 3.2 165 18.0
High school 206 55.8 115 38.3 187 74.8 508 55.3
First level degree 34 9.2 37 12.3 28 11.2 99 10.8
Second level degree 17 4.6 46 15.3 26 10.4 89 9.7
Smoking habits
Smoker 93 25.1 99 33.0 78 31.2 270 29.3
Ex-smoker 70 18.9 66 22.0 51 20.4 187 20.3
Nonsmoker 207 55.9 135 45.0 121 48.4 463 50.3
Alcohol consumption
Regular drinker 10 2.7 25 8.3 11 4.4 46 5.0
Occasional drinker 111 30.1 171 57.0 202 80.8 484 52.7
Ex-drinker 8 2.2 11 3.7 7 2.8 26 2.8
Non-drinker 240 65.0 93 31.0 30 12.0 363 39.5
1Numbers may not add up to the total due to missing data.
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sales data, with an overall difference of 0.39% (95% CI,
0.02–1.15) with the general population estimate.
Questionnaire validation
In order to evaluate questionnaire reproducibility, a ran-
dom sample of 32 controls who had taken part in the
study underwent a second interview by the same inter-
viewer after about a week (median 8 days, ranging from 4
to 18). The overall agreement on different questionnaire
items was good, ranging from 0.64 (95% CI, 0.39–0.81)
for skin diseases during the lifetime to 1 (95% CI, 0.999–
1) for other variables, including drugs exposure specific
questions.
Incidence of severe photosensitivity
reactions
Table 4 shows the incidence rate of severe photosensitiv-
ity reactions overall and by geographical region and in
relation to each suspected drug. A total of 8 severe photo-
sensitivity cases were reported in the population aged 18–
74 years of the 3 geographical areas during the 1-year
surveillance period, with an overall incidence rate of 4.81
cases per 10 million person-years (95% CI, 2.07–9.48),
ranging from 0 (95% CI, 0–38.48) for Prague to 2.73
(95% CI, 0.33–9.86) for Lombardy, and to 7.20 (95% CI,
2.64–15.66) for Paris. The incidence rate of cases linked
to topical ketoprofen was 0.61 per 10 million person-
years (95% CI, 0.01–3.35), ranging from 0 for Paris (95%
CI, 0–4.42) and Prague (95% CI, 0–38.48) to 1.36 (95%
CI, 0.03–7.61) for Lombardy. The incidence rate of
reactions linked to other topical NSAIDs as well as to sys-
temic NSAIDs in all regions involved was 0 per 10 mil-
lion person-years (95% CI, 0–2.21), while the incidence
of cases linked to other systemic or topical drugs was
4.21 per 10 million person-years (95% CI, 1.69–8.68).
Based on data from participating pharmacovigilance
databases, we estimated that 1 out of 7 reported photo-
sensitivity reactions, of any grade, required hospitalization
(data not shown). This proportion changed to 1 out of 5
for cases linked to topical ketoprofen.
Population attributable risk
PAR related to topical ketoprofen use and to other drugs
of interest is reported in Table 5. Based on our data, we
estimated that the overall PAR for severe photosensitivity
reactions leading to hospitalization linked to topical keto-
profen in the population aged 18–74 years of the 3 geo-
graphical areas was 11.92% (95% CI, 0.12–52.99) with
an OR of 21.69 (95% CI, 0.82–173.30), ranging from
4.72% (95% CI, 2.06–42.66) in Paris to 27.01% (95%
CI, 0.43–100) in Lombardy. The PAR for other topical
Table 2. Lifetime history of skin conditions for controls, by geographical region and overall.
Geographical region
Lombardy
(N = 370)
Paris area
(N = 300)
Prague area
(N = 250) Total (N = 920)
n* % n* % n* % n* %
Skin diseases
Atopic dermatitis 8 2.2 7 2.3 12 4.8 27 2.9
Psoriasis 7 1.9 14 4.7 4 1.6 25 2.7
Contact dermatitis 3 0.8 2 0.7 9 3.6 14 1.5
Urticaria 1 0.3 19 6.3 3 1.2 23 2.5
Polymorphous light eruptions 0 0.0 1 0.3 7 2.8 8 0.9
Other photosensitivity reactions 0 0.0% 4 1.3% 0 0.0 4 0.4
Herpes simplex 0 0.0% 5 1.7% 7 2.8 12 1.3
Vitiligo 2 0.5% 1 0.3% 1 0.4 4 0.4
Other skin diseases 1 0.3% 85 28.3% 11 4.4 97 10.5
Diseases predisposing to photosensitivity
Systemic lupus erythematosus 0 0.0 1 0.3 1 0.4 2 0.2
Other rheumatic disease 2 0.5 4 1.3 1 0.4 7 0.8
Allergic reaction to topical ketoprofen 1 0.3 2 0.7 0 0.0 3 0.3
Requiring hospitalization 1 0.3 0 0.0 0 0.0 1 0.1
Lifetime allergic reaction to other topical NSAIDs 2 0.5 2 0.7 2 0.8 6 0.7
Requiring hospitalization 0 0.0 0 0.0 0 0.0 0 0.0
Lifetime adverse effect to other medications 27 7.3 86 30.4 44 17.6 157 17.4
Requiring hospitalization 7 1.9 15 5.3% 6 2.4 28 3.1
1Unknown and missing data were excluded from the computation.
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NSAIDs was 2.47% (95% CI, 3.17–29.99) and the OR
equal to 1.82 (95% CI, 0–14.94), ranging from 1.31%
(95% CI, 8.96–35.13) in Paris to 14.18% (95% CI,
1.09–79.32) in Lombardy; for systemic ketoprofen it
was 1.67% (95% CI, 4.04–29.22) with an OR of 1.44
(95% CI, 0–11.64); for other systemic or topical drugs it
was 77.69% (95% CI, 14.00–98.89) and the OR equal to
8.92 (95% CI, 1.37–202.81).
Discussion
Our pilot study conducted in selected European areas,
showed that the incidence of photosensitivity reactions
leading to hospitalization was low for all the potential
causative factors, including topical ketoprofen, with esti-
mates lower than previously reported (Baudot et al. 1998;
Table 3. One-month drug exposure prevalence for controls, by geographical region and overall.
Geographical region
TotalLombardy Paris area Prague area
%* 95% CI %* 95% CI %* 95% CI %* 95% CI
Topical ketoprofen 0 0–0.99 2.02 0.74–4.34 0 0–1.46 0.65 0.24–1.42
Other topical NSAIDs 1.08 0.30–2.74 8.22 5.34–11.98 0 0–1.47 3.07 2.05–4.41
Other topical medications 0.27 0.01–1.50 9.25 6.18–13.16 1.20 0.25–3.47 3.40 2.32–4.79
Systemic NSAIDs 21.35 17.28–25.88 21.45 16.86–26.64 6.88 4.06–10.79 17.44 15.02–20.07
Ketoprofen 6.76 4.42–9.81 3.51 1.70–6.36 0 0–1.48 3.88 2.72–5.36
Other 14.59 11.16–18.61 17.19 13.00–22.08 6.88 4.06–10.79 13.30 11.15–15.70
Other systemic drugs 22.16 18.03–26.74 69.05 63.42–74.29 41.6 35.42–47.98 42.56 39.33–45.84
CI, confidence interval.
1Unknown and missing data were excluded from the computation.
Table 4. Severe photosensitivity incidence rates (per 10 million person-years) in total and linked to exposure to different drugs exposure, by geo-
graphical region and overall.
Geographical region
Total (N = 16,623,355)
Lombardy
(N = 7,325,746)
Paris area
(N = 8,338,986)
Prague area
(N = 958,623)
n r (95% CI) n r (95% CI) n r (95% CI) n r (95% CI)
Overall 2 2.73 (0.33–9.86) 6 7.20 (2.64–15.66) 0 0 (0–38.48) 8 4.81 (2.07–9.48)
Topical ketoprofen 1 1.36 (0.03–7.61) 0 0 (0–4.42) 0 0 (0–38.48) 1 0.61 (0.01–3.35)
Other topical NSAIDs 0 0 (0–5.04) 0 0 (0–4.42) 0 0 (0–38.48) 0 0 (0–2.21)
Systemic NSAIDs 0 0 (0–5.04) 0 0 (0–4.42) 0 0 (0–38.48) 0 0 (0–2.21)
Ketoprofen 0 0 (0–5.04) 0 0 (0–4.42) 0 0 (0–38.48) 0 0 (0–2.21)
Other 0 0 (0–5.04) 0 0 (0–4.42) 0 0 (0–38.48) 0 0 (0–2.21)
Other systemic or topical drugs 1 1.36 (0.03–7.61) 6 7.20 (2.64–15.66) 0 0 (0–38.48) 7 4.21 (1.69–8.68)
n, number of cases; r, incidence rates (per 10 million person-years); CI, confidence interval.
Table 5. Population attributable risk (PAR) linked to exposure to different drugs, by geographical region and overall.
Geographical region
Lombardy Paris area Prague area Total
PAR (95% CI) PAR (95% CI) PAR (95% CI) PAR (95% CI)
Topical ketoprofen 27.01% (0.43–100) 4.72% (2.06–42.66) NC 11.92% (0.12–52.99)
Other topical NSAIDs 14.18% (1.09–79.32) 1.31% (8.96–35.13) NC 2.47% (3.17–29.99)
Systemic ketoprofen 10.36% (7.25–76.39) 3.45% (3.64–39.86) NC 1.67% (4.04–29.22)
Other systemic or topical drugs 35.54% (25.65–96.79) 73.84% (45.56–100) NC 77.69% (14.00–98.89)
Some drug categories were excluded since PAR was not computable. NC, not computable; CI, confidence interval.
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Naldi et al. 1999; Veyrac et al. 2002; Diaz et al. 2006;
Noize et al. 2010).
There is a paucity of data about the incidence of severe
photosensitivity reactions in the general population. To
the best of our knowledge, only two surveys allowed to
calculate the reporting rate of drug-induced photosensi-
tivity reactions on a given population base. The first study
was an analysis of spontaneous reports in Italy in the per-
iod 1996–1997 (Naldi et al. 1999). The reporting rate of
photosensitivity reactions (limited to reactions classified
as “severe”, i.e., leading to hospitalization) was 0.09 per
100,000 inhabitants per year. The second survey was con-
ducted in the Biskay territory in Spain in the period
1996–2001 and was restricted to NSAIDs. A total of 83
photoallergic reactions attributed to NSAIDs were
observed over the analyzed period, with a rate of about
1.2 per 100,000 per year (Diaz et al. 2006). Ketoprofen
accounted for the vast majority of these reactions. A third
study conducted in France only focused on reactions to
ketoprofen with rates of any reaction ranging from 1.3 to
2.8 9 100,000 (Veyrac et al. 2002).
PAR indicates the proportion of cases of a disease
attributed to a given exposure in the population. Its mea-
sure depends on the prevalence of exposure to a causative
factor and the degree of association between the exposure
and the disease. In population terms, a rare exposure
associated with a high risk may be less serious, in the
total number of related events, than a very common
exposure with a lower risk. Our study showed that the
PAR linked to topical ketoprofen was almost 12%, indi-
cating that about one in eight cases of severe photosensi-
tivity reactions is attributable to the drug. The risk ratio
was higher compared to other NSAIDs and drugs of
interest.
In spite of some attempts at standardization, there are
no shared criteria for the diagnosis of photosensitivity
reactions. In our study, the severity of reactions was
judged based on hospitalization. This reduced the number
of total cases collected, since hospitalization policies
change over time and between countries. We estimated
that about 1 out of 5 cases of photosensitivity reactions
due to ketoprofene use was hospitalized.
In our study, information on drug exposure among
patients admitted for acute conditions not linked with
underlying chronic diseases, using questionnaires similar
to those proposed by the Slone Epidemiology Unit (Slone
et al. 1977), was taken as a reliable proxy for the preva-
lence of drug exposure in the general population. Com-
parisons made in the context of studies such as the SCAR
and the EuroSCAR projects have confirmed that the
prevalence of drug exposure among hospital controls
admitted for acute conditions are comparable to those
obtained from the general population (Kelly et al. 1995;
Auquier-Dunant et al. 2002; Mockenhaupt et al. 2008). In
our study, the prevalence of exposure to topical ketopro-
fen was found to be in accordance with the national sales
data.
Our study was a pilot one. Based on collected data, it
could be computed that at least 26 cases should be col-
lected with a case : control ratio of 1:100 (2600 controls)
in order to have enough power to reduce the 95% CI
width of the PAR estimate to 30% or lower. The feasibil-
ity of a large European study clearly depends on the
number of cases that one could collect during a reason-
ably short period of time, and, on the number of controls
recruited per case. The rate of hospitalization for photo-
sensitivity reactions appear to be quite low. Consequently,
the main study as designed in the protocol was deemed
not feasible. As an alternative to a hospital-based case–
control study, one may consider to conduct the study in
the outpatient setting. In such a community-based study,
other factors such as cross-sensitization (e.g. among keto-
profene and octocrylene) and poly-sensitization could be
also assessed.
Conclusions
To summarize, we documented that the incidence of sev-
ere photosensitivity reactions leading to hospitalization
was low and that among topical NSAIDs, topical ketopro-
fen was the leading cause even if it accounted for a lim-
ited number of cases of the reaction. Our study was a
pilot one. A different study design focusing on the
outpatient setting could better estimate the incidence of
photosensitivity reactions in the general population.
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